Exosomes: The Rising Star in Aesthetic Medicine
By Crystal Wilson , NP In recent years, the aesthetic industry has witnessed a remarkable shift towards more natural, less invasive treatments. Among the most exciting advancements in this
Tuesday, August 02, 2011
Washington — The Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA, Merz Aesthetics) for temporary improvement of moderate to severe glabellar lines, Medscape Today reports.
According to a Merz statement, the approval is based on the results of two multicenter U.S. clinical trials involving 547 healthy adults. In both studies, Xeomin® injections significantly improved the appearance of glabellar lines in 30 days when compared with placebo. Headache was the most common adverse reaction observed.
Under the brand name Bocouture, Xeomin® is already approved in 14 European countries including Germany, the United Kingdom, France, Italy and Spain. It was FDA-approved in 2010 for the treatment of cervical dystonia and blepharospasm.
https://www.facialesthetics.org/blog/fda_oks_xeomin_for_frown_lines
By Crystal Wilson , NP In recent years, the aesthetic industry has witnessed a remarkable shift towards more natural, less invasive treatments. Among the most exciting advancements in this
By Kaitlyn Konsur , RN In recent years, the popularity of dermal fillers has increased, promising satisfying results for fine lines, wrinkles, and facial volume loss. With minimal downtime
By Sydney Gatta, RN In the realm of facial aesthetics and rejuvenation, innovative treatments continue to emerge, offering patients a plethora of options to enhance their appearance and combat